Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 4/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043257 | 0.93 | CTSK (0.56) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL14637585 | 0.90 | CTSK (0.55) | CTSKCTSSCTSBCTSLAKT1 | |
| SCHEMBL10135741 | 0.90 | CTSK (0.55) | CTSKCTSSCTSBCTSLAKT1 | |
| SCHEMBL14684989 | 0.89 | CTSK (0.51) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL23680477 | 0.88 | CTSK (0.59) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL23275571 | 0.88 | CTSK (0.59) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL23275569 | 0.88 | CTSK (0.59) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL18978665 | 0.88 | CTSK (0.53) | CTSKCTSSCTSBCTSLAKT1 | |
| SCHEMBL12947678 | 0.86 | CTSK (0.54) | CTSKCTSSCTSBCTSLREN | |
| SCHEMBL18978668 | 0.85 | CTSK (0.51) | CTSKCTSSCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101661-B2 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | KEMPHARM, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2101571-B1 | ORNITHINE CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM INC (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-7776917-B2 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776917-B2 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090234018-A1 | Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same | SHIRE LLC | 2009-09-17 | — | — | US | disclosed |
| US-20090234018-A1 | Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same | SHIRE LLC | 2009-09-17 | — | — | US | disclosed |
| WO-2008073918-A1 | NON-STANDARD AMINO ACID CONJUGATES OF AMPHETAMINE AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC18A2, SLC6A19, SLC6A2 | CTSK 3469/4885CTSS 2715/4885CTSB 2954/4885 |
| US-20090234018-A1 | Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same | SLC6A3, AADAT, SLC6A2 | CTSK 2102/4885CTSS 1682/4885CTSB 1864/4885 |
| US-20080139653-A1 | Non-standard amino acid conjugates of amphetamine and processes for making and using the same | SLC6A3, AADAT, SLC6A2 | CTSK 2102/4885CTSS 1682/4885CTSB 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.